Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Clinical trial NCT04447469 · COMPLETED
Trial details
- NCT number
- NCT04447469
- Sponsor
- Kiniksa Pharmaceuticals International, plc
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-28
- Primary completion
- 2021-11-12
- Enrollment
- 814
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.